Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

用于肥胖成年人的每日一次口服GLP-1受体激动剂奥曲欣普仑

Sean Wharton et al.

The New England journal of medicine. 2023 Sep 7;389(10):877-888.

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date

迄今为止用于治疗二型糖尿病的口服GLP-1受体激动剂的研发进展：现有证据分析

Christina Antza et al.

Drug design, development and therapy. 2019 Aug 22:13:2985-2996.

Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023

口服GLP-1受体激动剂（塞马鲁肽片）不良事件的 real-world 研究：基于 2019 年至 2023 年FAERS 数据库分析

Si Xiong et al.

Diabetes therapy : research, treatment and education of diabetes and related disorders. 2024 Aug;15(8):1717-1733.

GLP-1 Receptor Agonist Therapy in Cystic Fibrosis-Related Diabetes: A Case Report

格列奈类胰岛素促分泌剂治疗囊性纤维化相关糖尿病的一例报告

Gida Ayada et al.

Diabetes technology & therapeutics. 2024 Oct 3.

Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications

术前使用GLP-1受体激动剂与术后呼吸道并发症的风险关系

Anjali A Dixit et al.

JAMA. 2024 May 21;331(19):1672-1673.

A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist

用另一种GLP-1受体激动剂治疗多年后出现Dulaglutide诱发的急性间质性肾炎一例报告

Muralikrishna Gangadharan Komala

Clinical diabetes : a publication of the American Diabetes Association. 2022 Fall;40(4):508-510.

Dulaglutide

杜拉格利汀

.

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease

GLP-1受体激动剂与非酒精性脂肪肝病

Jinmi Lee et al.

Diabetes & metabolism journal. 2012 Aug;36(4):262-7.